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Abstract
Objective Stratified medicine refers to the use of tests that predict treatment response to drive treatment decisions for indi-
vidual patient. The pharmacoeconomic implications of this approach in schizophrenia are unknown. We aimed to assess 
the cost-effectiveness of a hypothetical stratified medicine algorithm (SMA) compared with treatment as usual (TAU), for 
patients with schizophrenia who failed a first-line antipsychotic.
Methods A decision analytic model with embedded Markov process was constructed, which simulated the health and cost 
outcomes for patients followed SMA or TAU over a lifetime horizon, from healthcare and social care perspective. In the base-
case analysis, sensitivity and specificity of the stratifier were both set as 60%. Extensive sensitivity analyses were conducted 
to test the impact of uncertainty around the value of important parameters. The primary outcome was the incremental cost 
per quality-adjusted life year (QALY) gained.
Results When both sensitivity and specificity of the stratified test were set at 60%, SMA appeared to be the optimal strategy 
as it produces more QALYs and incurs lower costs than TAU. This is robust to all scenarios tested. At a willingness-to-pay 
threshold of £20,000 per QALY, the probability for SMA to be the optimal strategy is 82.4%.
Conclusions Our results suggest that use of any stratifier with a sensitivity and specificity over 60% is very likely to be cost-
effective comparing to TAU, for psychotic patients who failed a first-line antipsychotic. This finding, however, should be 
interpreted with caution due to lack of evidence for clozapine as a second-line antipsychotic.
Keywords Schizophrenia · Stratified medicine · Health economics · Cost-effectiveness · Markov model
JEL Classification D61
Introduction
Stratified medicine refers to the use of a stratifier (e.g. 
a biomarker or other predictive marker) to guide treat-
ment choices. The mainstay of treatment for schizophre-
nia is antipsychotic medication, however, about one-third 
of patients with schizophrenia are treatment resistant 
(TRS)—they do not respond adequately to conventional 
antipsychotics other than clozapine [1]. Clozapine is the 
only drug with established efficacy in reducing symp-
toms and the risk of relapse for adults with TRS [2]. 
In addition, clozapine is also superior for negative and 
cognitive symptoms, as well as reducing suicidality and 
all-cause mortality [3]. Owing to safety concerns regard-
ing the risk of neutropenia and agranulocytosis, the use 
of clozapine in most countries is restricted to patients 
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who fail two non-clozapine antipsychotics at adequate 
doses [2, 4–6]. Although theoretically patients could be 
trialled on two non-clozapine antipsychotics in the space 
of a few months, in practice there is frequently a delay of 
several years before clozapine is prescribed [7]. There is 
emerging evidence, that ineffective antipsychotic treat-
ment early in disease leads to worse long-term outcomes 
[8], and specifically that delay in prescribing clozapine 
to patients who are treatment resistant confers a poor 
outcome [9]. Thus, a stratifier which could predict TRS 
accurately and early might allow better decision making 
and lead to improved patients’ outcomes.
Significant efforts have been made to identify different 
stratifiers for predicting antipsychotic treatment responses 
for patients with schizophrenia, including immunologi-
cal, neuroimaging and pharmacogenetic tests. However, 
the effect size of most stratifiers is small [10]. Recently, 
a large genome-wide association study conducted by the 
Chinese Antipsychotics Pharmacogenomics Consortium 
(CAPOC) showed that a combination of five novel loci 
could predict antipsychotic treatment response, with a 
sensitivity of 65% and a specificity of 69% [11]. It is 
therefore important to estimate whether using a test with 
this level of accuracy is sufficient to achieve cost-effec-
tive improvements in quality of life or not. This study 
aims to answer this question by estimating and comparing 
the long-term health and cost outcomes for patients who 
are treated with and without guidance of a hypothetical 
stratifier under different scenarios. The hypothetical strat-
ifier can be any tests, such as immunological, neuroimag-
ing or pharmacogenetic tests.
Methods
This study was reported according to the CHEERS recom-
mendations for reporting health economic evaluations [12].
Population
The base case for the analysis consisted of a hypothetical 
cohort of adult patients with schizophrenia who failed a first-
line conventional (i.e. non-clozapine) antipsychotic in the 
UK. It was decided that a stratifier would be more useful for 
patients who failed a first-line conventional antipsychotic 
than patients who are treatment-naïve, because the latter 
patient group has a high response rate to first-line conven-
tional antipsychotic (ranges from 67.4 to 75.4% as reported 
by published literature [13, 14]).
Competing treatment strategies
Two treatment strategies were considered in the model: 
treatment as usual (TAU) and a stratified medical algorithm 
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Fig. 1  Protocol of treatment as usual (TAU) and stratified medical 
algorithm (SMA) for schizophrenia patients who failed a first-line 
conventional antipsychotic. a The conventional antipsychotics con-
sidered in the model include: olanzapine, amisulpride, aripiprazole, 
paliperidone, risperidone, haloperidol and flupenthixol decanoate. b 
Predicted to respond to a second-line conventional antipsychotic. c 
Predicted not to respond to a second-line conventional antipsychotic
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(SMA). Both strategies are described briefly below, and are 
visually shown in Fig. 1a, b, respectively. The primary out-
comes of this analysis are lifetime cost and quality-adjusted 
life year (QALYs) gained for patients who received one of 
the alternative treatment strategies (TAU or SMA).
TAU 
Patients would be treated according to the National Institute 
for Health and Care Excellence (NICE) schizophrenia guide-
line 2014 [2]. Thus, all patients who failed a first-line con-
ventional antipsychotic would be treated with a second-line 
conventional antipsychotic. For this study, the seven antipsy-
chotics included in the network meta-analysis conducted by 
the NICE schizophrenia guideline were modelled as second-
line conventional antipsychotics, including olanzapine, ami-
sulpride, aripiprazole, paliperidone, risperidone, haloperidol 
and flupenthixol decanoate [2]. Patients who did not respond 
to a second-line antipsychotic would be switched to clozap-
ine; while patients who did not respond to, or experienced an 
intolerable adverse reaction to clozapine, would be switched 
to another conventional antipsychotic.
SMA
All patients who failed a first-line conventional antipsychotic 
would undergo a stratified test designed to predict their 
response to second-line conventional antipsychotics. Patients 
predicted to be AP2 responders (positive test result) would 
be switched to a second-line conventional antipsychotic; 
while patients predicted not to be AP2 responders (negative 
test result) would be switched immediately to clozapine, thus 
bypassing the second treatment trial. Patients who failed a 
second-line conventional antipsychotic would be switched 
to clozapine; while patients who failed clozapine would be 
switched to another conventional antipsychotic.
Key impacts of the stratifier modelled in the study
In order to estimate the lifetime impact of the stratifier on 
total cost and QALYs, the following impacts of using a strat-
ifier were modelled: clinical benefits, clinical harms, cost 
of stratifier, and cost impact on other resource use. A brief 
description of each impact is presented below. The clini-
cal benefit of using SMA considered in the model is that 
clozapine responders who are correctly identified as AP2 
non-responders (true negative) can initiate clozapine once 
they fail a first-line antipsychotic, without having to try an 
ineffective second-line antipsychotic first. Therefore, the 
costs saved from treating otherwise relapsed patients, the 
increase in QALYs arising from spending less time in a state 
of relapse, and their reduced mortality accruing from the use 
of clozapine, were modelled. The potential harm of using 
SMA is, if the stratifier is not 100% accurate, some AP2 
responders might be wrongly identified as AP2 non-respond-
ers (false negative) and switched to clozapine unnecessar-
ily. AP2 responders who were wrongly predicted to be AP2 
non-responders (false negatives), and were thus prescribed 
clozapine, would have a 71.16% probability of responding to 
clozapine and therefore remain on it [13, 15]. The remaining 
28.84% patients who do not respond to clozapine would be 
offered a second-line conventional antipsychotic, which they 
would respond to. Compared to most conventional antipsy-
chotics included in the model, clozapine is associated with 
higher adherence rate and lower incidence of acute extrapy-
ramidal symptoms (EPS), but is more likely to cause other 
adverse reactions, including weight gain and diabetes [2]. 
Furthermore, patients on clozapine are at risk of neutropenia 
and thus need to be monitored frequently. There is therefore 
a cost to being unnecessarily prescribed clozapine, which 
was included in the model.
Model structure
In order to capture the key impacts of using a stratifier (as 
described above), a decision analytic model with a Markov 
process embedded was developed using TreeAge 2014 
(TreeAge Software, Williamstown, MA). Within the Markov 
process, events of interest are modelled as transitions from 
one health state to another. The time period of the model is 
divided into cycles of time, for example a year for this study, 
and at each cycle, probabilities are assigned of remaining 
in the same state or moving to a different state within the 
model. A 1-year cycle was chosen because most antipsy-
chotic discontinuation happened within a year after the initi-
ation of a new antipsychotic [16]. The economic model built 
for the NICE schizophrenia guideline also adopts a 1-year 
cycle [2]. In our model, eleven mutually exclusive health 
states were included. The transition between different health 
states for patients in the TAU arm and the SMA arm are 
illustrated in Figs. 2 and 3, respectively. Which health state 
the patient would be in depends on the patient’s subgroup 
(AP2 responder, clozapine responder, or non-responder) and 
which antipsychotic treatment the patient is currently on 
(conventional antipsychotic, clozapine, or no antipsychotic 
due to non-adherence). Each of the health states is assigned a 
cost and effectiveness value that patients accrue while in that 
state. For each treatment, the overall costs and effectiveness 
are calculated on the basis of the total length of time patients 
spend in each health state over the time horizon. Both costs 
and QALYs were discounted at an annual rate of 3.5%, as 
recommended by NICE [17], to reflect society’s preference 
for costs to be incurred in the future rather than the present, 
and for benefits to be experienced in the present rather than 
the future. Use of antipsychotics are associated with a wide 
range of adverse physical and mental health events. Based on 
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the incidence rate, magnitude of health and cost impact and 
data availability, four adverse events of antipsychotic medi-
cations were selected for this model: weight gain, acute EPS, 
diabetes and neutropenia (for patients on clozapine only).
It was assumed that within the target population, there are 
three patient subgroups:
• AP2 responder, patients who will respond to a second-
line conventional antipsychotic.
• Clozapine responder, patients who will fail to respond 
to a second line antipsychotic but will subsequently 
respond to clozapine.
• Non-responder, patients who will not respond to any 
existing antipsychotics including clozapine.
Wherever a patient responded to an antipsychotic, 
it was assumed that they would continue to receive the 
same antipsychotic in the following cycles. Patients 
who responded to a second-line antipsychotic but did 
not adhere to their medication were assumed to remain 
without antipsychotic treatment until they experienced a 
relapse, after which they were assumed to return to the 
same antipsychotic.
Input data
Cost-effectiveness analysis requires four types of data: clini-
cal evidence, health-related preferences (utilities), healthcare 
resource use and costs. A summary of the key parameters 
used in the model is reported in Table 1 and briefly described 
below; while a detailed description of all parameters used in 
the model is reported in Online Resource 1. In the base-case 
analysis, both the sensitivity and specificity of the stratifier 
were set at 60% (similar to the accuracy data reported by the 
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Fig. 2  State transition diagram of the Markov model for patients in the TAU arm. AP conventional antipsychotic, CLZ clozapine
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study conducted by CAPOC [11]), with a range of 0–100% 
was tested in sensitivity analyses. There is a lack of clinical 
evidence about patients’ response to a second-line antipsy-
chotic after failing a first-line antipsychotic. According to a 
recent literature review [14], there are only two trials which 
examined patients’ response to a second-line antipsychotic 
after failing a first-line antipsychotic: one is a naturalistic 
study conducted by Agid et al. [13], and another is an open-
label treatment with clozapine in first-episode schizophrenia 
and schizophreniform disorder (OPTiMiSE) trial [14]. It was 
decided that the data reported by Agid et al. is more appro-
priate for this model for two reasons: (1) Agid et al. has a 
larger sample size than the OPTiMiSE trial (60 vs 39, num-
ber of patients who were switched to a second-line antipsy-
chotic after failing a first-line antipsychotic); (2) The results 
of the OPTiMiSE trial indicated that for patients who did 
not achieve remission with a first-line antipsychotic within 
4 weeks, switching to a second-line conventional antipsy-
chotic did not improve their response rate—or in another 
word, for patients who failed a first-line antipsychotic, the 
proportion of AP2 responder is nearly zero. The lower the 
proportion of AP2 responder, the higher the proportion of 
clozapine responder and non-responder, and the more cost-
effective the stratifier, as the key benefit of using the stratifier 
is to help clozapine responders to initiate clozapine earlier 
compared to the current practice. Therefore, to be conserva-
tive about the potential benefits of using the stratifier, the 
data reported by Agid et al. was used in the base case analy-
sis, while a different range of data was tested in sensitivity 
analyses. Based on the data reported by Agid et al., it was 
calculated that for patients who failed a first-line antipsy-
chotic, 16.67% of them responded to a conventional second-
line antipsychotic (risperidone or olanzapine was used in the 
study), 62.50% responded to clozapine, and 20.83% did not 
respond to any antipsychotic tested in the study. Therefore, 
in the model, it was assumed that the proportion of different 
patient subgroups are: AP2 responder (16.67%), clozapine 
responder (62.50%) and non-responder (20.83%). The pro-
portion of positive and negative test results depend on the 
sensitivity and specificity of the stratifier, and the proportion 
of AP2 responders. Under a stratifier with 60% sensitivity 
and specificity, and assuming 16.67% of target population 
are AP2 responders, 43.33% patients will get positive results 
(10.00% are true positive and 33.33% are false positive), 
while 56.67% patients will get negative results (50.00% are 
true negative and 6.67% are false negative). Patients’ prob-
ability of non-adherence to conventional antipsychotics and 
probability of developing adverse events were obtained from 
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Fig. 3  State transition diagram of the Markov model for patients in the SMA arm. AP conventional antipsychotic, CLZ clozapine
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Table 1  Summary of key parameters used in model
Parameters Base-line 
value
Range tested in one-way  
or two-way sensitivity analysis
Distribution Source
Diagnostic efficacy of predictive test
 Sensitivity 
(proportion 
of second-
line antip-
sychotic 
responders 
that are 
correctly 
identified 
as such)
0.60 0–1.00 Assumed fixed Estimate of what may 
be achievable
 Specificity 
(propor-
tion of 
second-line 
antipsy-
chotic non-
responders 
that are 
correctly 
identified 
as such)
0.60 0–1.00 Assumed fixed Estimate of what may 
be achievable
Distribution of patients who failed a first-line antipsychotic by subsequent response/non-response
 Clozapine 
responder
62.50% 0%–79.15% Dirichlet distribution (n = 21.0) Agid et al. [15]
 AP2 
responder
16.67% N/A Dirichlet distribution (n = 5.6) As above
 Clozapine 
non-
responder
20.83% N/A Dirichlet distribution (n = 7.0) As above
Response to different antipsychotics in misclassified individuals
 AP2 
responder’s 
response to 
clozapine
71.16% 0–1 Beta distribution (SD assumed to be 50% of 
mean value)
Calculated from Agid 
et al. [15] and McE-
voy et al. [1]
 AP2 non-
responder 
response to 
second-line 
antipsy-
chotics
0% N/A Assumed fixed Estimate
Cost data
 Cost of predictive test £500.00 £100.00–
1,000.00
Gamma distribution (SD 
assumed to be 50% of mean 
value)
Estimate
Interventions Base-line value Range tested in one-way or 
two-way sensitivity analysis
Distribution Source
 Annual cost of treating patients 
with active psychosis
£39,141 N/A As above Uplifted from the NICE 
schizophrenia guide-
line [2]
 Annual cost of treating remitted 
patients
£15,086 £10,000–£39,141 As above As above
Health-related quality of life data
 Relapse 0.4790 0.1900–0.6040 Beta distribution (SD: 0.0330) Briggs et al. [24]
 Stable schizophrenia 0.8650 0.8650–0.9190 Beta distribution (SD: 0.0210) As above
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the network meta-analyses reported in the NICE schizophre-
nia guideline [2].
Utility data were obtained from a UK study which 
reported separate utility scores for stable or relapsed schizo-
phrenia patients with or without adverse events of antipsy-
chotics [18]. For costing data, the model took the perspective 
of the UK health and social care system, as recommended 
by NICE [17]. All costs were reported in 2017 UK pounds. 
The cost of the stratifier was assumed to be £500 per patient 
(an estimate of the cost of a magnetic resonance spectros-
copy scan, which is considered to be the higher end of the 
likely cost of a stratifier) with a range of £100–1000 tested in 
sensitivity analyses [19]. Unit costs were based on the NHS 
reference costs 2016–17 [20], prescription cost analysis 
(England) 2017 [21] or the Unit Costs of Health and Social 
Care 2017 [22]. Resource quantities were mainly informed 
by the NICE schizophrenia guideline 2014 [2].
Sensitivity analysis
The credibility of the results of economic analysis largely 
relies on the validity of input data. Sensitivity analyses can 
test the effect of changes in the input data on the observed 
results. If, after performing sensitivity analyses, the find-
ings are consistent with those from the baseline analysis 
and would lead to similar conclusions about the cost-effec-
tiveness of different strategies, we can be reassured that the 
uncertainty of input data has little impact on the primary 
conclusions. For this study, three types of sensitivity analy-
ses were conducted: one-way sensitivity analysis which 
assess the impact of uncertainty around the value of each 
individual parameter, two-way sensitivity analysis which 
assess the impact of uncertainty around the value of two 
correlated parameters (e.g. sensitivity and specificity of 
the stratifier), and probabilistic sensitivity analysis (PSA) 
which examine the impact of joint uncertainty of multiple 
parameters simultaneously. A summary of all parameters 
tested in sensitivity analysis is reported in Online Resource 
1, Table 1.
Model verification and validation
A summary of the activities conducted for model verification 
and validation is presented in Table 2.
A complete list of all parameters used in the model is reported in Online Resource 2, Table 1
Table 1  (continued)
Interventions Base-line value Range tested in one-way or 
two-way sensitivity analysis
Distribution Source
Other input data
 Annual discount rate for both 
costs and outcomes
0.0350 0–0.050 Assumed fixed NICE guideline manual 
[19]
 Cycle length 1 year N/A Assumed fixed Estimate
 Number of cycles 80 10–100 Assumed fixed Estimate
Table 2  Verification and 
validation process and people 
involved
HJ Huajie Jin, JM James MacCabe, PM Paul McCrone
Verification and validation process People involved
1. Check appropriateness of the model structure JM and PM
2. Check appropriateness of data source JM and PM
3. Compare data used in the model against the evidence sources HJ
4. Check model logic (white-box testing) HJ
5. Check the plausibility of the intermediate and final outputs, including  
results of sensitivity analyses (black-box testing)
HJ, JM and PM
6. Compare results with published literature HJ
Table 3  Incremental costs and QALYs per person by treatment strat-
egy
Strategy Total Costs (£) Total QALYs Incremen-
tal cost (£)
Incre-
mental 
QALYs
TAU 510,239 16.15 – –
SMA 502,876 16.25 − 7363 0.10
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Results
The base-case analysis results are presented in Table 3. 
Compared to TAU, use of the SMA produced 0.10 more 
QALYs and incurred £7363 lower costs per person. The 
results of one-way and two-way sensitivity analysis are 
reported in detail in Online Resource 2 and is summarised 
below. One-way sensitivity analysis showed that our conclu-
sion (SMA is more cost-effective than TAU) was robust to 
all parameters tested. Two-way sensitivity analysis shows 
that even when the sensitivity of the stratifier is 0%, as long 
as the specificity of the stratifier is no less than 11.50%, 
SMA is still more cost-effective than TAU. If the sensitivity 
of the stratifier is 50%, as long as the specificity of the test is 
no less than 6%, SMA is more cost-effective than TAU. The 
result of PSA is shown in Fig. 4. If the NHS was not willing 
to attach any monetary value to QALY gains, the likelihood 
for SMA to be the most cost-effective option is 76.62%. As 
a unit improvement is valued at higher levels this likelihood 
increases. At a WTP threshold of £20,000 per QALY, there 
is a 83.04% likelihood that SMA is the most cost-effective 
option.
Discussion
Main findings and interpretation
Significant efforts have been made to identify stratifiers for 
predicting antipsychotic treatment responses for patients 
with schizophrenia. However, little is known about how 
accurate such a stratifier needs to be to achieve cost-effective 
improvements in quality of life. To the best of our knowl-
edge, only one previous study has assessed the cost-effec-
tiveness of a stratifier for schizophrenia patients, which is a 
modelling study conducted by Perlis et al. [23]. The stratifier 
assessed was a genetic test that can identify individuals with 
greater likelihood of responding to second-line conventional 
antipsychotics, with a sensitivity of 95.9% and a specific-
ity of 38.3%. Perlis et al. found that applying the test to 
treatment-naïve patients and using clozapine as a first-line 
antipsychotic for those predicted to respond to clozapine is 
more effective but also more expensive, comparing with no 
test and reversing clozapine as a third-line antipsychotic. 
However, the study conducted by Perlis et al. had some 
limitations: (1) it did not consider the health or cost impact 
of any adverse events of antipsychotics, which might have 
important impacts on the cost-effectives results; (2) PSA was 
not conducted to examine the impact of joint uncertainty 
of multiple parameters simultaneously; (3) this study was 
Fig. 4  Cost-effectiveness 
acceptability curves showing 
probability that each strategy 
is most cost-effective option 
at different willingness-to-pay 
(WTP). SMA Stratified medi-
cine algorithm. TAU Treatment 
as usual
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published in 2005, therefore, it has limited relevance to the 
current context, due to rapidly changing nature of treatments, 
health services, evidence base and unit costs. No previous 
studies have assessed the cost-effectiveness of a stratifier for 
schizophrenia patients who fail a first-line antipsychotic. In 
order to fill the gap, we used decision-analytic modelling to 
estimate the cost-effectiveness of a SMA for schizophrenia 
patients who failed a first-line antipsychotic, over a life-time 
time horizon from the health sector and social care perspec-
tive. Results indicate that the stratified medicine algorithm 
was more cost effective that treatment as usual, when both 
the sensitivity and specificity of the stratifier was set at 60%. 
One surprising finding of this study is, even when the sensi-
tivity of the stratifier is set to 0%, as long as the specificity of 
the stratifier is no less than 11.50%, SMA is still more cost-
effective than TAU. This was mainly because the proportion 
of patients who would respond to clozapine is much larger 
than the proportion of patients who would only respond to 
a second-line conventional antipsychotic. A 0% sensitivity 
means none of the AP2 responders are correctly identified 
as such—all of them are identified as AP2 non-responders 
and therefore be prescribed with clozapine. According to 
Agid’s study [13] and the CATIE trial [15], 16.67% of the 
target population are AP2 responders; and 71.16% of AP2 
responders would also respond to clozapine. This means, 
only those AP2 responders who do not respond to clozap-
ine (16.67%*(1–71.16%) = 4.81%) are adversely affected 
by the poor sensitivity of the stratifier, and even then, they 
are only on clozapine for 1 year in our model, before being 
switched to a non-clozapine antipsychotic, to which they 
would respond. For those AP2 responder who also respond 
to clozapine (16.67%*71.16% = 11.86%), our model shows 
that although they are slightly better-off with a conventional 
second-line antipsychotic comparing to clozapine, the over-
all magnitude of cost and QALY difference is very small. 
The specificity of the test, in this model, is its ability in cor-
rectly identifying AP2 non-responders, which includes clo-
zapine responders and non-responders. According to Agid’s 
study [13], clozapine responders comprise 62.50% of the 
target population. A 11.50% specificity means, comparing 
to TAU, 7.19% (= 11.50%*62.50%) of the target population 
received the right treatment (clozapine) one cycle earlier, 
and therefore results in lower cost and higher QALY gains. 
To sum up, comparing to TAU, use of a stratifier with 0% 
sensitivity and 11.50% specificity results in worse outcomes 
for 4.81% patients (AP2 responders wrongly identified as 
clozapine responders, and who do not respond to clozapine) 
and better outcomes for 7.19% patients (clozapine respond-
ers correctly identified as AP2 non-responders). Therefore, 
after weighing up the clinical benefits, clinical harms and 
cost implications of the stratifier, SMA is considered to be 
more cost-effective than TAU.
According to a recent systematic review [14], there are 
only two trials which examined patients’ response to a sec-
ond-line antipsychotic after failing a first-line antipsychotic: 
Agid et al. [13] and the OPTiMiSE trial [14]. Both studies 
found that for patients who failed a first-line conventional 
antipsychotic, their response to a second-line conventional 
antipsychotic is poor—in fact, the OPTiMiSE trial found 
that for patients who did not achieve remission with a first-
line antipsychotic within 4 weeks, it might be better for them 
to continue their current antipsychotic, rather than being 
switched to a second-line conventional antipsychotic. The 
findings of these two studies, combined with the result of our 
model (a stratifier with very low sensitivity and specificity 
is still considered to be cost-effective) raises the question 
of whether a stratifier is necessary for patients who failed a 
first-line antipsychotic or not—using clozapine as a second-
line treatment without any stratifier might turn out to be 
more cost-effective, compared to use of a stratifier with low 
sensitivity and/or specificity. Although a few studies have 
argued the potential benefits of using clozapine as a second-
line or even first-line treatment [24–26], there is currently a 
lack of high-quality evidence about clozapine’s efficacy for 
schizophrenia who failed a first-line antipsychotic. Further 
research is urgently needed to establish clozapine’s clinical 
efficacy and safety profile for patients as a second-line treat-
ment. With publication of such results, the input data of the 
present analysis can be updated to shed light on whether 
clozapine should be used as a second-line antipsychotic.
Strengths and limitations
To our knowledge, this is the first study to explore the phar-
macoeconomic implications of using a stratified medicine 
approach in schizophrenia patients who failed a first-line 
antipsychotic. A major strength of this study was the col-
lective use of the state-of-the-art methodology and most 
up-to-date data to evaluate the cost-effectiveness of a hypo-
thetical stratifier. Decision analytic modelling provides a 
framework to quantify and synthesize the clinical benefits, 
clinical harms and cost implications of the stratifier. Com-
prehensive sensitivity analyses have been conducted to test 
the uncertainty of the result. Therefore, commissioners and 
clinical researchers can be reassured that the conclusion of 
this paper is robust to large changes or errors in the input 
parameters.
There are a number of limitations of the economic model 
presented here, the majority of which derive from limita-
tions in the evidence base used to populate the model. For 
example: (1) patients’ responses to second-line antipsychot-
ics were calculated based on the data for 60 schizophrenia 
patients included in the Agid et al. [13], as there is a lack of 
larger trials which specifically assessed patients’ responses 
to a second-line antipsychotic after failing a first-line 
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antipsychotic. There is uncertainty about the generalizability 
of the results reported by Agid et al. due to its small sample 
size; (2) patients’ probability of developing adverse events 
were obtained from the network meta-analyses reported in 
the NICE schizophrenia guideline [2]. It was noted that the 
population included in those network meta-analyses were 
‘general’ schizophrenia patients in remission, some of 
whom might have been on antipsychotics for many years. 
It is unknow whether those patients would have different 
probability of developing adverse events, compared with 
our target population. However, in this study, the limitation 
related to parameter uncertainty has been partially mitigated 
by extensive sensitivity analyses. Secondly, discontinua-
tion of antipsychotics due to intolerable adverse events was 
only modelled for clozapine, but not for other conventional 
antipsychotics. This simplification is against the use of 
clozapine, and thus against the use of stratifier, as the key 
benefit of using the stratifier is that clozapine responders 
who are correctly identified as AP2 non-responders can ini-
tiate clozapine sooner than the current practice. The base 
case results show that even when this simplification was 
used, SMA still dominates TAU, which demonstrates the 
robustness of our base case conclusion. Thirdly, the cost 
and health impacts of adverse events of antipsychotics have 
not been fully captured. Other than the four adverse events 
modelled in this study (i.e. weight gain, diabetes, acute EPS 
and neutropenia), there are other adverse events which might 
impact on patients’ QALY and cost outcomes, such as tar-
dive dyskinesia, sexual dysfunction, increase in prolactin 
levels, and agranulocytosis. Even for those adverse events 
which were considered in the model, the impacts of com-
plications of those adverse events were not fully captured: 
for example, the impact of complications of diabetes (e.g. 
myocardial infarction and stroke etc.) on mortality were not 
considered in the model. Fourthly, besides the health and 
social care costs that were considered in this analysis, SMA 
is likely to have an impact on the wider societal costs (such 
as costs borne to the criminal justice system and productiv-
ity losses for schizophrenia patients and their carers). When 
wider societal costs were considered, the gap between treat-
ment cost of remitted patients and relapse patients is likely 
to widen [27], and thus making SMA more cost-effective.
Conclusion
Our results suggest that use of any stratifier (e.g. immu-
nological, neuroimaging or pharmacogenetic tests) with 
a sensitivity and specificity over 60% is very likely to be 
cost-effective comparing to TAU, for psychotic patients 
who failed a first-line antipsychotic. This finding, however, 
should be interpreted with caution due to lack of evidence 
for clozapine as a second-line antipsychotic.
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